Sep 05, 2025 9:00 am EDT Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need
Sep 04, 2025 4:01 pm EDT Mineralys Therapeutics Announces Closing of Upsized $287.5 Million Underwritten Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Sep 02, 2025 9:33 pm EDT Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock
Aug 12, 2025 4:05 pm EDT Mineralys Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Aug 04, 2025 4:05 pm EDT Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025
Jun 30, 2025 11:17 am EDT Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat
Jun 17, 2025 7:00 am EDT Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria
May 24, 2025 4:30 am EDT Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025)
May 20, 2025 8:00 am EDT Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection
